While the DEGAM recommendation, which is three years older, advocates PSA-based early detection for PCa only for those patients who actively request it, the interdisciplinary S3 guideline allows physician’s active initiative, provided that the patient is thoroughly informed about possible advantages and disadvantages of this PCa screening measure (13, 14). The gene discussed is KLK3; the disease is posterior cortical atrophy.